Pfizer acquires Redvax

Tuesday, January 6, 2015

Pfizer has acquired a controlling interest in Redvax, a spinoff from Redbiotec, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

[Read More]